The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Will The Market Value Of The Next-Generation Antibody Therapeutics Market Grow Between 2026 And 2030?
The next-generation antibody therapeutics market size has experienced rapid growth in recent years. It is projected to expand from $7.56 billion in 2025 to $8.35 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.4%. The increase observed in the historic period can be attributed to factors such as a rise in monoclonal antibody approvals, the growing prevalence of cancer, an expansion of biologics manufacturing capacity, increased investment in pharmaceutical research and development, and enhanced regulatory pathways for biologics.
The next-generation antibody therapeutics market is projected for significant expansion over the coming years. By 2030, this market is anticipated to reach $12.63 billion, exhibiting a compound annual growth rate (CAGR) of 10.9%. Several factors will contribute to this projected increase, including innovations in antibody engineering technologies, a growing need for targeted treatments, the rising occurrence of chronic and autoimmune conditions, the expansion of clinical research in developing regions, and increasing collaborations between biotechnology and pharmaceutical firms. Key trends anticipated during this period involve the broadening of bispecific and multispecific antibody platforms, the increased use of antibody-drug conjugates in cancer treatment, a heightened emphasis on high-affinity and extended-duration antibodies, an expanding pipeline of clinical trials for rare and orphan diseases, and a move towards customized antibody-based therapeutic approaches.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12678&type=smp
Which Key Drivers Are Affecting The Next-Generation Antibody Therapeutics Market Development?
The rising occurrence of chronic ailments is anticipated to fuel the expansion of the next-generation antibody therapeutics market. These are conditions persisting for a year or more, necessitating ongoing medical attention, limiting daily functions, or a combination thereof. Next-generation antibody therapeutics offer a therapeutic role for individuals with chronic illnesses, delivering more focused care which benefits patient outcomes. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, it was projected that by the year 2050, the number of individuals aged 50 years and older who have at least one chronic illness will surge by 99.5%, rising to 142.66 million. Consequently, the increasing prevalence of chronic diseases is propelling the growth of the next-generation antibody therapeutics market.
How Is The Next-Generation Antibody Therapeutics Market Segmented Across Different Segment Categories?
The next-generation antibody therapeutics market covered in this report is segmented –
1) By Types Of Antibodies: Monoclonal Antibodies, Polyclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Types
2) By Therapeutic Area: Oncology, Autoimmune Diseases, Infectious Diseases, Neurodegenerative Disorders, Other Therapeutic Areas
3) By End-User: Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users
Subsegments:
1) By Monoclonal Antibodies: IgG Monoclonal Antibodies, IgM Monoclonal Antibodies
2) By Polyclonal Antibodies: Serum-Derived Polyclonal Antibodies, Hybridoma-Derived Polyclonal Antibodies
3) By Bispecific Antibodies: Dual-Targeting Antibodies, Single-Chain Variable Fragment (scFv) Antibodies
4) By Antibody-Drug Conjugates (ADCs): Targeted ADCs, Payload Types
5) By Other Types: Nanobodies, Engineered Antibodies
What Trends Are Transforming The Next-Generation Antibody Therapeutics Market?
Major companies within the next-generation antibody therapeutics market are concentrating on creating technological breakthroughs, such as the proprietary Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology, to improve protein identification and characterization, which in turn leads to more focused and efficient treatments. These advancements are designed to enhance therapeutic outcomes, decrease expenses, and address intricate diseases with greater accuracy. Molecular Indexing of Proteins by Self-Assembly (MIPSA) is a method that organizes protein molecules into structured arrangements for more effective analysis and quantification. It boosts the sensitivity and precision of protein detection, proving valuable in research and diagnostic fields. For example, in January 2024, Infinity Bio, Inc., a US-based biotechnology company, released a next-generation antibody profiling platform that employs MIPSA technology for rapid, cost-effective analysis of immune responses, intending to deepen disease understanding and customize treatment strategies.
Which Organizations Play A Role In The Next-Generation Antibody Therapeutics Market Landscape?
Major companies operating in the next-generation antibody therapeutics market are Pfizer Inc., F. Hoffmann‑La Roche Ltd., Bristol‑Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Genentech Inc., Kyowa Hakko Kirin Co. Ltd., Seagen Inc., Seattle Genetics Inc., Xencor Inc., ImmunoGen Inc., Genmab A/S, Zymeworks Inc., NBE‑Therapeutics AG, Daiichi Sankyo Company Limited, Merck & Co Inc., Novartis AG, AbCellera Biologics Inc., Sotio Biotech, F‑Star Therapeutics Ltd., ADC Therapeutics SA, Harbour BioMed
Get The Full Next-Generation Antibody Therapeutics Market Report:
Which Region Is The Largest In The Next-Generation Antibody Therapeutics Market?
North America was the largest region in the next-generation antibody therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation antibody therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Next-Generation Antibody Therapeutics Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Next-Generation Antibody Therapeutics Market 2026, By The Business Research Company
Next Generation Sequencing Market Report 2026
https://www.thebusinessresearchcompany.com/report/next-generation-sequencing-global-market-report
Next Generation Military Power Supply Market Report
Next Generation Computing Market Report
https://www.thebusinessresearchcompany.com/report/next-generation-computing-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model